Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Patterns of Local-Regional Failure after Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

Yang P, Xu T, Gomez DR, Deng W, Wei X, Elhalawani H, Jin H, Guan F, Mirkovic D, Xu Y, Mohan R, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Aug 27. pii: S0360-3016(18)33637-X. doi: 10.1016/j.ijrobp.2018.08.031. [Epub ahead of print]

PMID:
30165127
2.

DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non-small-cell lung cancer.

Jiang XE, Xu T, Wei Q, Li P, Gomez DR, Court LE, Liao Z.

Chronic Dis Transl Med. 2018 Jun 13;4(2):109-116. doi: 10.1016/j.cdtm.2018.05.003. eCollection 2018 Jun.

3.

Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.

Boonyawan K, Gomez DR, Komaki R, Xu Y, Nantavithya C, Allen PK, Mohan R, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):919-926. doi: 10.1016/j.ijrobp.2018.04.012. Epub 2018 Apr 12.

PMID:
29976504
4.

Proton therapy for early-stage non-small cell lung cancer (NSCLC).

Gomez DR, Li H, Chang JY.

Transl Lung Cancer Res. 2018 Apr;7(2):199-204. doi: 10.21037/tlcr.2018.04.12. Review.

5.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 May 21. doi: 10.1158/1078-0432.CCR-17-3279. [Epub ahead of print]

PMID:
29784675
6.

Functional promoter rs189037 variant of ATM is associated with decrease in lung diffusing capacity after irradiation for non-small-cell lung cancer.

Lopez Guerra JL, Song YP, Nguyen QN, Gomez DR, Liao Z, Xu T.

Chronic Dis Transl Med. 2018 Mar 16;4(1):59-66. doi: 10.1016/j.cdtm.2018.02.006. eCollection 2018 Mar.

7.

Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer.

Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Komaki R, Hu Y, Hahn SM, Liao Z.

Cancer Med. 2018 Jun;7(6):2247-2255. doi: 10.1002/cam4.1349. Epub 2018 May 9.

8.

Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy.

Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR.

Clin Lung Cancer. 2018 Jul;19(4):e517-e528. doi: 10.1016/j.cllc.2018.03.012. Epub 2018 Mar 17.

PMID:
29685701
9.

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.

Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):558-563. doi: 10.1016/j.ijrobp.2018.02.022. Epub 2018 Mar 2.

PMID:
29680255
10.

Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer.

Yue J, McKeever M, Sio TT, Xu T, Huo J, Shi Q, Nguyen QN, Komaki R, Gomez DR, Pan T, Wang XS, Liao Z.

Clin Transl Radiat Oncol. 2017 May 11;4:1-7. doi: 10.1016/j.ctro.2017.04.001. eCollection 2017 Jun.

11.

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV.

Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 6.

12.

Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS.

Qual Life Res. 2018 Jun;27(6):1563-1570. doi: 10.1007/s11136-018-1834-3. Epub 2018 Mar 16.

PMID:
29549533
13.

Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.

Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z, Xu T, Gomez DR, Komaki R, Liao Z, Wei Q.

J Thorac Oncol. 2018 May;13(5):660-675. doi: 10.1016/j.jtho.2018.01.028. Epub 2018 Feb 15.

14.

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R.

J Clin Oncol. 2018 Jun 20;36(18):1813-1822. doi: 10.1200/JCO.2017.74.0720. Epub 2018 Jan 2.

PMID:
29293386
15.

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.

Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667-676. doi: 10.1016/j.ijrobp.2017.06.2450. Epub 2017 Jun 27.

PMID:
29280461
16.

Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.

Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B.

Eur J Cardiothorac Surg. 2018 May 1;53(5):960-966. doi: 10.1093/ejcts/ezx427.

PMID:
29211849
17.

Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer.

Jensen GL, Yost CM, Mackin DS, Fried DV, Zhou S, Court LE, Gomez DR.

Radiother Oncol. 2018 Feb;126(2):362-367. doi: 10.1016/j.radonc.2017.11.006. Epub 2017 Nov 28.

PMID:
29196095
18.

Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.

Zhou R, Xu T, Nguyen QN, Liu Y, Yang J, Komaki R, Gomez DR, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):452-461. doi: 10.1016/j.ijrobp.2017.10.003. Epub 2017 Oct 12.

PMID:
29174428
19.

Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In Vivo Imaging Biomarkers.

Niedzielski JS, Yang J, Mohan R, Titt U, Mirkovic D, Stingo F, Liao Z, Gomez DR, Martel MK, Briere TM, Court LE.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1013-1020. doi: 10.1016/j.ijrobp.2017.07.005. Epub 2017 Jul 8.

PMID:
29063837
20.

Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer.

Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR.

J Am Stat Assoc. 2017;112:11-23. doi: 10.1080/01621459.2016.1176926. Epub 2017 May 3.

21.

Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):70-79. doi: 10.1016/j.ijrobp.2017.05.022. Epub 2017 May 22.

22.

Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.

Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):128-135. doi: 10.1016/j.ijrobp.2017.05.037. Epub 2017 Jun 1.

PMID:
28816138
23.

Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer.

Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR.

Clin Exp Metastasis. 2017 Jun;34(5):315-322. doi: 10.1007/s10585-017-9850-1. Epub 2017 Jul 25.

PMID:
28744603
24.

Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer.

Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Hahn S, Liao Z.

Oncotarget. 2017 Jun 27;8(26):43080-43090. doi: 10.18632/oncotarget.17904.

25.

Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer.

Fang P, Swanick CW, Pezzi TA, Liao Z, Welsh J, Lin SH, Gomez DR.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):433-441. doi: 10.1016/j.prro.2017.03.005. Epub 2017 Mar 9.

PMID:
28428017
26.

Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.

Fang P, He W, Gomez DR, Hoffman KE, Smith BD, Giordano SH, Jagsi R, Smith GL.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):748-757. doi: 10.1016/j.ijrobp.2017.01.228. Epub 2017 Feb 1.

27.

Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.

Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):900-907. doi: 10.1016/j.ijrobp.2016.12.022. Epub 2016 Dec 21.

28.

Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials.

Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):770-777. doi: 10.1016/j.ijrobp.2016.11.035. Epub 2016 Nov 27.

29.

The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy.

Yang J, Xu T, Gomez DR, Jeter M, Levy LB, Song Y, Hahn S, Liao Z, Yuan X.

Transl Oncol. 2017 Apr;10(2):197-202. doi: 10.1016/j.tranon.2016.12.009. Epub 2017 Feb 9.

30.

Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base.

Pezzi TA, Mohamed AS, Fuller CD, Blanchard P, Pezzi C, Sepesi B, Hahn SM, Gomez DR, Chun SG.

Ann Surg Oncol. 2017 May;24(5):1419-1427. doi: 10.1245/s10434-017-5786-6. Epub 2017 Feb 2.

PMID:
28154950
31.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients.

Vial MR, Khan KA, O'Connell O, Peng SA, Gomez DR, Chang JY, Rice DC, Mehran R, Jimenez CJ, Grosu HB, Ost DE, Eapen GA.

Ann Thorac Surg. 2017 May;103(5):1600-1605. doi: 10.1016/j.athoracsur.2016.09.106. Epub 2016 Dec 24.

32.

Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.

Reddy JP, Tang C, Shih T, Kim B, Kim C, Nguyen QN, Welsh J, Benveniste M, Zhang J, Liao Z, Gomez DR.

Clin Lung Cancer. 2017 Mar;18(2):141-148. doi: 10.1016/j.cllc.2016.11.003. Epub 2016 Nov 10.

33.

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.

Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW.

Cancer Res. 2017 Feb 15;77(4):839-850. doi: 10.1158/0008-5472.CAN-15-3142. Epub 2016 Nov 7.

34.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

35.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.

Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU.

J Thorac Oncol. 2017 Feb;12(2):375-382. doi: 10.1016/j.jtho.2016.10.013. Epub 2016 Oct 26.

36.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV.

Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.

37.

Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.

Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY.

Pract Radiat Oncol. 2017 May - Jun;7(3):e195-e203. doi: 10.1016/j.prro.2016.09.005. Epub 2016 Sep 13.

PMID:
27743801
38.

(18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy.

Niedzielski JS, Yang J, Liao Z, Gomez DR, Stingo F, Mohan R, Martel MK, Briere TM, Court LE.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):670-8. doi: 10.1016/j.ijrobp.2016.07.012. Epub 2016 Jul 21.

39.

Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions.

Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR.

Pract Radiat Oncol. 2017 Jan - Feb;7(1):63-71. doi: 10.1016/j.prro.2016.05.009. Epub 2016 Jun 3.

PMID:
27637136
40.

Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW.

Cancer J. 2016 Jul-Aug;22(4):257-66. doi: 10.1097/PPO.0000000000000210. Review.

41.

Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma-An Analysis of the International Thymic Malignancies Interest Group Retrospective Database.

Rimner A, Yao X, Huang J, Antonicelli A, Ahmad U, Korst RJ, Detterbeck F, Gomez DR.

J Thorac Oncol. 2016 Oct;11(10):1785-92. doi: 10.1016/j.jtho.2016.06.011. Epub 2016 Jun 23.

42.

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM.

J Clin Oncol. 2016 Aug 10;34(23):2761-8. doi: 10.1200/JCO.2016.67.2675. Epub 2016 Jun 20.

43.

Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.

Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1226-35. doi: 10.1016/j.ijrobp.2016.01.065. Epub 2016 Mar 18.

PMID:
27209498
44.

Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer.

Tang C, Liao Z, Hess K, Chance WW, Zhuang Y, Jensen G, Xu T, Komaki R, Gomez DR.

Acta Oncol. 2016 Aug;55(8):1022-8. doi: 10.3109/0284186X.2016.1154602. Epub 2016 Apr 8.

PMID:
27055359
45.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

46.

Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z.

J Pain Symptom Manage. 2016 May;51(5):832-8. doi: 10.1016/j.jpainsymman.2015.12.316. Epub 2016 Feb 16.

47.

Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.

Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z.

Clin Lung Cancer. 2016 Jul;17(4):253-262.e5. doi: 10.1016/j.cllc.2015.11.008. Epub 2015 Nov 22.

PMID:
26732495
48.

Objectively Quantifying Radiation Esophagitis With Novel Computed Tomography-Based Metrics.

Niedzielski JS, Yang J, Stingo F, Martel MK, Mohan R, Gomez DR, Briere TM, Liao Z, Court LE.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):385-93. doi: 10.1016/j.ijrobp.2015.10.010. Epub 2015 Oct 14.

49.

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW.

Mol Ther Nucleic Acids. 2015 Dec 15;4:e270. doi: 10.1038/mtna.2015.47.

50.

PDL1 Regulation by p53 via miR-34.

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW.

J Natl Cancer Inst. 2015 Nov 17;108(1). pii: djv303. doi: 10.1093/jnci/djv303. Print 2016 Jan.

Supplemental Content

Loading ...
Support Center